文献速递前列腺癌

对初次多参数磁共振靶向穿刺与系统穿刺均阴性且PI-RADS≥3病灶患者的随访——一项提高前列腺癌检出率的EAU-YAU研究

Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions - an EAU-YAU study enhancing prostate cancer detection.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-11-05

这项回顾性多中心研究纳入694例初次mpMRI阳性(PI-RADS≥3)且MRI靶向穿刺与系统穿刺均阴性的患者,按随访方案分为三组。总体前列腺癌和临床显著前列腺癌检出率分别为26.8%和19.3%;第3组2年和5年无前列腺癌生存率最高(94%和84%),多因素分析显示第1、2组风险显著高于第3组(p<0.01)。

要点

  • 初次mpMRI阳性但靶向及系统穿刺均阴性者,随访中总体前列腺癌检出率为26.8%,临床显著前列腺癌为19.3%。
  • 按临床和影像学触发进行mpMRI随访及穿刺的第3组,2年及5年无前列腺癌生存率分别为94%和84%。
  • 多因素分析显示第1组和第2组前列腺癌及临床显著前列腺癌风险显著高于第3组(p<0.01)。

核心结论

  • mpMRI阳性但靶向穿刺和系统穿刺均阴性的患者,其前列腺癌和临床显著前列腺癌检出率随随访方案不同而变化,需要量身定制的随访策略。

研究设计与样本

  • 回顾性多中心研究,纳入来自10家三级转诊中心的694例患者,初次mpMRI阳性(PI-RADS≥3)且MRI靶向穿刺和系统穿刺均为阴性。
  • 患者按随访方式分为三组:第1组为无新mpMRI的前列腺再穿刺,第2组为标准化的第二次前列腺mpMRI及后续再穿刺,第3组为基于临床和影像学触发进行mpMRI和穿刺的随访。

主要发现

  • 总体前列腺癌检出率为26.8%,临床显著前列腺癌检出率为19.3%,不同PI-RADS组检出率不同。
  • 第3组2年和5年无前列腺癌生存率分别为94%和84%,无临床显著前列腺癌生存率分别为96%和86%。
  • 多因素分析显示,第1组和第2组前列腺癌及临床显著前列腺癌风险显著高于第3组(p<0.01)。
  • 前列腺癌和临床显著前列腺癌的临床与影像学预测因素包括较高年龄、前列腺体积、PI-RADS评分、非典型小腺泡增生(ASAP)的存在以及初次穿刺时靶向穿刺和系统穿刺针数较少。

临床怎么用

  • 作者认为,针对这一临床情境,量身定制的随访策略对优化管理至关重要。

局限性

  • 回顾性设计。
  • 随访决策依赖临床和影像学触发因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the detection and predictors of prostate cancer (PCA) and clinically significant prostate cancer (csPCA) in patients with positive multiparametric MRI (mpMRI) followed by a negative MRI - guided target biopsy (TB) and systematic biopsy (SB). MATERIALS AND METHODS: This retrospective multicenter study included 694 patients from 10 tertiary referral centers with an initial positive mpMRI (PI-RADS ≥ 3) and negative results on both MRI-TB and SB. Patients were classified into three groups based on follow-up: Group 1 (prostate re-biopsy without new mpMRI), Group 2 (standardized second prostate mpMRI and subsequent re-biopsy), and Group 3 (follow-up with mpMRIs and biopsy based on clinical and radiological triggers). The primary outcomes were the detection of any PCA and csPCA during follow up. Study groups were compared according to their probability of PCA and csPCA assessed with the ERSPC-MRI risk calculator. Statistical analysis included Kaplan - Meier analysis, Cox regression, and multivariable analysis for the detection of (cs)PCa. RESULTS: The overall detection of PCA and csPCA was 26.8% and 19.3%, respectively, with varying rates in different PI-RADS groups. Group 3 had the highest 2-year and 5-year PCA-free survival (94 and 84%) and csPCA - free survival (96 and 86%). Multivariable analysis revealed a significantly higher risk of PCA and csPCA in Group 1 and 2 compared to Group 3 (p < 0.01). Clinical and radiological predictors for PCA and csPCA included higher age, prostate volume, PI-RADS score, the presence of atypical small acinar proliferation (ASAP), and a smaller number of TB and SB performed during the initial biopsy. Study limitations, include the retrospective design and reliance on clinical and radiological triggers for follow-up decisions. CONCLUSIONS: Patients with positive mpMRI but negative TB and SB results exhibit varying rates of PCA and csPCA depending on the follow up scheme. Tailored follow-up strategies are essential for optimal management in this clinical scenario.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Zattoni F, Gandaglia G, van den Bergh RCN, et al. Follow-up on patients with initial negative mpMRI target and systematic biopsy for PI-RADS ≥ 3 lesions - an EAU-YAU study enhancing prostate cancer detection. Prostate Cancer Prostatic Dis. 2024. PMID: 39501078. doi:10.1038/s41391-024-00904-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。